Discordance between Activated Partial Thromboplastin Time and Anti-factor Xa in Unfractionated Heparin Monitoring: Literature Review

Debora Purwasista Ciptasari; Rizaldy Taslim Pinzon; Agung Endro Nugroho

doi:10.22146/farmaseutik.v20i4.98746

Discordance between Activated Partial Thromboplastin Time and Anti-factor Xa in Unfractionated Heparin Monitoring: Literature Review

https://doi.org/10.22146/farmaseutik.v20i4.98746

Debora Purwasista Ciptasari⁽¹⁾, Rizaldy Taslim Pinzon⁽²⁾, Agung Endro Nugroho^(3*)

(1) Master Program in Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada
(2) Bethesda Hospital, Yogyakarta
(3) Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Anticoagulants are prescribed very frequently, but their use is often associated with adverse drug reactions. The optimal monitoring of heparin is unknown, either by aPTT or anti-Xa levels. This paper compares which anti-Xa or aPTT most closely correlates with patients on intravenous heparin. This review also compares the achievement of target goals of unfractionated heparin (UFH) using aPTT and anti-Xa tests. Literature searching was started in June 2024 and ended in July 2024 through some online scientific databases: Scopus, PubMed, Google Scholar, Science Direct, and Willey Online Library. This review includes fifteen studies, at least involving 2,938 patients or 94,038 sets of measurements. The review demonstrates that anti-Xa outperforms aPTT in achieving the therapeutic range of unfractionated heparin, time to therapeutic goal, and dose modification.

Keywords

anti-xa; apt; UFH; monitoring; discordance

Full Text:

PDF

References

Adatya, S., Uriel, N., Yarmohammadi, H., Holley, C. T., Feng, A., Roy, S. S., Reding, M. T., John, R., Eckman, P., & Zantek, N. D. (2015). Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support. JACC: Heart Failure, 3(4), 314–322. https://doi.org/10.1016/j.jchf.2014.11.009

Arnouk, S., Altshuler, D., Lewis, T. C., Merchan, C., Smith, D. E. I., Toy, B., Zakhary, B., & Papadopoulos, J. (2020). Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support. ASAIO Journal, 66(3), 300. https://doi.org/10.1097/MAT.0000000000001004

Aubron, C., Chapalain, X., Bailey, M., Board, J., Buhr, H., Cartwright, B., Dennis, M., Hodgson, C., Forrest, P., & McIlroy, D. (2023). Anti-factor-xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: A secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial. Critical Care Explorations, 5(11), e0999.

Derbalah, A., Duffull, S., Newall, F., Moynihan, K., & Al-Sallami, H. (2019). Revisiting the Pharmacology of Unfractionated Heparin. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-019-00751-7

Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012). Parenteral Anticoagulants. Chest, 141(2), e24S-e43S. https://doi.org/10.1378/chest.11-2291

Gombar, S., Boothroyd, D., Krishnan, A., Sharifi, H., Hsu, J., & Zehnder, J. (2019). Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management. Blood, 134(Supplement_1), 712. https://doi.org/10.1182/blood-2019-132112

Kindelin, N. M., Anthes, A. M., Providence, S. M., Zhao, X., & Aspinall, S. L. (2021). Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time. The Annals of Pharmacotherapy, 55(5), 575–583. https://doi.org/10.1177/1060028020961503

Kulig, C. E., Schomer, K. J., Black, H. B., & Dager, W. E. (2021). Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients. ASAIO Journal (American Society for Artificial Internal Organs: 1992), 67(4), 411–415. https://doi.org/10.1097/MAT.0000000000001246

Lever, R., Mulloy, B., & Page, C. P. (Eds.). (2012). Heparin—A Century of Progress (Vol. 207). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-23056-1

Mahmoud, L., Zullo, A. R., McKaig, D., & Berard-Collins, C. M. (2016). Concordance between activated partial thromboplastin time and antifactor Xa assay for monitoring unfractionated heparin in hospitalized hyperbilirubinemic patients. Rhode Island Medical Journal (2013), 99(3), 33.

McLaughlin, K., Rimsans, J., Sylvester, K. W., Fanikos, J., Dorfman, D. M., Senna, P., Connors, J. M., & Goldhaber, S. Z. (2019). Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. Clinical and Applied Thrombosis/Hemostasis, 25, 107602961987603. https://doi.org/10.1177/1076029619876030

McRae, H. L., Militello, L., & Refaai, M. A. (2021). Updates in Anticoagulation Therapy Monitoring. Biomedicines, 9(3), 262. https://doi.org/10.3390/biomedicines9030262

Ratano, D., Alberio, L., Delodder, F., Faouzi, M., & Berger, M. M. (2019). Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thrombosis Research, 175, 53–58.

Saito, T., Hayakawa, M., Kumano, O., Honma, Y., Murashita, M., Kato, J., Fukui, S., Takahashi, M., Takahashi, Y., Tsuchida, T., Mizugaki, A., Takauji, S., Hayamizu, M., Yoshida, T., Katabami, K., Wada, T., & Maekawa, K. (2023). Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: A retrospective observational study. Journal of Intensive Care, 11(1), 54. https://doi.org/10.1186/s40560-023-00701-3

Samuel, S., Allison, T. A., Sharaf, S., Yau, G., Ranjbar, G., Mckaig, N., Nguyen, A., Escobar, M., & Choi, H. A. (2016). Antifactor Xa levels vs. Activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. Journal of Clinical Pharmacy and Therapeutics, 41(5), 499–502. https://doi.org/10.1111/jcpt.12415

Smythe, M. A., Priziola, J., Dobesh, P. P., Wirth, D., Cuker, A., & Wittkowsky, A. K. (2016). Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 41(1), 165–186. https://doi.org/10.1007/s11239-015-1315-2

Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016). Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 41(1), 32–67. https://doi.org/10.1007/s11239-015-1317-0

Tan, S., White, H. D., & Layland, J. (2022). Heparin use in acute coronary syndromes and cardiovascular interventions: Habit or evidence based? European Heart Journal, 43(10), 1008–1011. https://doi.org/10.1093/eurheartj/ehab896

Thalappil, V., Anand, J., Keepanasseril, A., & Kar, R. (2023). Standardization of Anti-Xa Assay and its Comparison with Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin Therapy. Indian Journal of Hematology and Blood Transfusion, 1–5.

Ucar, E. Y., Akgun, M., Araz, O., Tas, H., Kerget, B., Meral, M., Kaynar, H., & Saglam, L. (2015). Comparison of LMWH Versus UFH for Hemorrhage and Hospital Mortality in the Treatment of Acute Massive Pulmonary Thromboembolism After Thrombolytic Treatment: Randomized Controlled Parallel Group Study. Lung, 193(1), 121–127. https://doi.org/10.1007/s00408-014-9660-z

Vo, T., Bello, A., Ragan, M., Flanagan, J., & Johnson, D. (2023). Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 80(Suppl 2), S77–S83. https://doi.org/10.1093/ajhp/zxac351

Whitman-Purves, E., Coons, J. C., Miller, T., DiNella, J. V., Althouse, A., Schmidhofer, M., & Smith, R. E. (2018). Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 24(2), 310–316. https://doi.org/10.1177/1076029617741363

Yarmohammadi, H., Feng, A. J., Alraies, C. M., Thenappan, T., Colvin, M., John, R., Eckman, P., Pritzker, M., & Adatya, S. (2014). Abstract 19105: Basis for Biochemical Discordance Between Activated Partial Thromboplastin Time and Anti-factor Xa in Patients with Continuous Flow Left Ventricular Assist Device on Unfractionated Heparin Infusion. Circulation, 130(suppl_2). https://doi.org/10.1161/circ.130.suppl_2.19105

DOI: https://doi.org/10.22146/farmaseutik.v20i4.98746